- AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Randomized, Multicenter Study of KYV101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis (KYSA-7)
This study is testing a new type of cell therapy called KYV101 for people with serious forms of multiple sclerosis (MS) that are getting worse. It compares this new treatment with existing MS medications to see how well it works and if it's safe.
For: Primary or Secondary Progressive Multiple SclerosisGermany · Italy · Belgium - AuthorisedPhase I and Phase II (Integrated)- Other
Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis: A two-stage interventional, prospective, open-label, phase I/II trial in patients with active, treatment refractory, ANCA-IgG-positive vasculitis
This study is testing a new cell therapy called KYV-101 for a condition called ANCA vasculitis that hasn't responded to other treatments. It's looking at how safe the treatment is and if it can help reduce the antibodies that cause the condition.
For: ANCA-IgG-positive ANCA associated vasculitisGermany